The July 6 awards carry a $4.03 exercise price, a 10-year term, and four-year vesting under Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals said it issued inducement awards to new employees effective July 6, 2026, consisting of options to purchase an aggregate of 750,000 shares of common stock under its 2019 Inducement Equity Incentive Plan. The company said the plan is used exclusively for grants to individuals who were not previously X4 employees, and that the awards were approved by the Compensation Committee of the Board of Directors as inducements material to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $4.03 per share, equal to X4's closing stock price on July 6. Vesting is spread over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. X4, which focuses on rare hematology diseases, said it has developed mavorixafor, an oral CXCR4 antagonist approved in the U.S. and EU as XOLREMDI for patients with WHIM syndrome, and is running the global pivotal Phase 3 4WARD trial in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for chronic neutropenia.